Osteoarthritis (OA) affects ~90% of people older than 65, and associated costs top $100 billion annually in the U.S. One treatment available for large cartilage defects seen in osteoarthritis is osteochondral allograft (OCA) transplantation. Currently, tissue banks store OCAs at 4 degree C and implantation is recommended within 28 days after procurement due to significant loss in chondrocyte viability after this time. Because mandatory disease screening protocols typically take 14 days to complete, the window for surgical implantation is narrow, which severely limits clinical use. The MOPS(TM) protocol can maintain OCAs for 56 days. In this study, OCAs stored using MOPS(TM) and SOC protocol were assessed for cell viability and metabolic biomarker production
